ABHD16A — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL2235103	0.74	2/20
SCHEMBL2233406	0.72	2/20
SCHEMBL2233598	0.72	2/20
SCHEMBL7046228	0.72	2/20
SCHEMBL2237968	0.72	2/20
SCHEMBL6551854	0.68	2/20
SCHEMBL7578034	0.68	2/20
SCHEMBL7040935	0.68	2/20
SCHEMBL6551089	0.67	2/20
SCHEMBL6552566	0.65	2/20
SCHEMBL4398899	0.65	2/20
SCHEMBL7043879	0.65	2/20
SCHEMBL7048013	0.65	2/20
SCHEMBL7047523	0.64	2/20
SCHEMBL2603463	0.63	2/20
SCHEMBL7044439	0.63	2/20
SCHEMBL7040780	0.63	2/20
SCHEMBL7046263	0.63	2/20
SCHEMBL6552790	0.63	2/20
SCHEMBL6599090	0.62	2/20

Clinical trials — most relevant to ABHD16A by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Acid Lipase Replacement Investigating Safety and Efficacy (ARISE) in Participants With Lysosomal Acid Lipase Deficiency	PHASE3	COMPLETED
Betaine and Peroxisome Biogenesis Disorders	PHASE3	COMPLETED
Bezafibrate Trial in CPT2 Deficiency	PHASE3	UNKNOWN
Cholic Acid for Hepatic Steatosis in Lipodystrophy	PHASE2	COMPLETED
Orlistat for the Treatment of Type I Hyperlipoproteinemia	PHASE2	COMPLETED
Effect of Gemfibrozil on Serum Glycosylphosphatidylinositol (GPI) Phospholipase D and Triglycerides	PHASE1	COMPLETED
CS-121 APOC3 Base Editing in FCS	EARLY_PHASE1	RECRUITING
the Role of plin5 in the Development of Nonalcoholic Fatty Liver Disease.	nan	UNKNOWN
High-Density Lipoprotein (HDL) Treatment Study	nan	COMPLETED
Abnormal Lipids - Causes and Effects	nan	RECRUITING
The LD Lync Study - Natural History Study of Lipodystrophy Syndromes	nan	RECRUITING
Genomic Dissection of a QTL Affecting the Lipid Profile	nan	WITHDRAWN
Identification of a New Gene Involved in Hereditary Lipodystrophy	nan	COMPLETED
Genes Involved in Lipid Disorders	nan	COMPLETED
The Efficacy of Pedometer-motivated Physical Activity for the Management of Patients With MASLD.	nan	ENROLLING_BY_INVITATION
Registry Gangliosidoses	nan	UNKNOWN
Lipodystrophy Connect Patient Registry	nan	COMPLETED
Genetic Determinants:Low HDL, High Triglycerides, Obesity	nan	COMPLETED
Combining Gene Variants to Improve Risk Prediction for Metabolic (Dysfunction)- Associated Fatty Liver Disease and Its Progression to Cirrhosis in Indian Individuals With Type 2 Diabetes	nan	COMPLETED
Familial Partial Lipodystrophy Study	nan	COMPLETED
Natural History of Uncommon Dyslipidemias, Rare Lipid Disorders and Unusual Atherosclerotic Conditions	nan	RECRUITING
Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML)	nan	WITHDRAWN
An Observational Study of Patients With Lysosomal Acid Lipase Deficiency/Cholesteryl Ester Storage Disease Phenotype	nan	COMPLETED
Lipa Gene Mutation in PED-LIPIGEN (Pediatric FH Subjects)	nan	UNKNOWN
Screening of Healthy Adults for Genetic Variations That Control Fatty Acid Processing	nan	COMPLETED
Genetic Origin of Lipid Disorders	nan	UNKNOWN
Circadian Rhythms in Human Adipose	nan	RECRUITING
PCD New Gene Discovery	nan	COMPLETED
A Retrospective Natural History Study of Patients With Lysosomal Acid Lipase Deficiency/Wolman Phenotype	nan	COMPLETED
Hydroxychloroquin (HCQ) in chILD of Genetic Defect	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a ABHD16A binder may also engage these)

Protein	Name	Similarity
Q1JPD2	—	1.000	Q1JPD2 →
Q4R8P0	—	1.000	Q4R8P0 →
Q5R6S0	—	1.000	Q5R6S0 →
Q6MG55	—	1.000	Q6MG55 →
Q9Z1Q2	—	1.000	Q9Z1Q2 →
O00623	—	0.976	O00623 →
A7E2V1	—	0.975	A7E2V1 →
Q9BSK4	—	0.975	Q9BSK4 →
Q96MI9	—	0.974	Q96MI9 →
Q4FZX0	—	0.974	Q4FZX0 →
Q9CZT4	—	0.974	Q9CZT4 →
Q28DH9	—	0.974	Q28DH9 →
Q6DDX8	—	0.973	Q6DDX8 →
F1ND48	—	0.973	F1ND48 →
MAP4K2	Mitogen-activated protein kinase kinase kinase kinase 2	0.973	landscape →
Q91YR5	—	0.973	Q91YR5 →
Q6NX27	—	0.973	Q6NX27 →
Q6DFS0	—	0.972	Q6DFS0 →
A6QNT4	—	0.972	A6QNT4 →
Q969U6	—	0.972	Q969U6 →
Q3ZBT2	—	0.972	Q3ZBT2 →
Q6DC53	—	0.971	Q6DC53 →
Q8BYZ7	—	0.971	Q8BYZ7 →
Q9UJ98	—	0.971	Q9UJ98 →
Q5NDF0	—	0.971	Q5NDF0 →
Q58E26	—	0.971	Q58E26 →
Q9WTK3	—	0.971	Q9WTK3 →
Q9CV28	—	0.971	Q9CV28 →
Q4V7A9	—	0.971	Q4V7A9 →
A5PJM5	—	0.971	A5PJM5 →